Key Insights from the Final FDA Computer Software Assurance Guidance
We have listed 5 key insights into this update
1. What are the main changes in the FDA’s final CSA guidance (2026)?
The final CSA guidance clarifies, rather than replaces, the 2022 draft. Key updates include a new definitions section (cloud models like SaaS, PaaS, IaaS), explicit inclusion of AI/ML systems, expectations for cybersecurity evidence, instructions on when 21 CFR Part 11 applies, expanded vendor oversight recommendations, and a new SaaS-based PLM (Product Life Cycle Management System) example. The final version emphasizes risk-based assurance, digital records, and change-management expectations.
2. Does the final CSA guidance require validating SaaS and cloud-based tools?
Yes, when cloud or SaaS tools affect the quality system, product, patient safety, or regulated records, they fall inside CSA scope. If the tool is outside the QMS (e.g., purely administrative), it may not require validation. The guidance stresses determining scope using risk assessment.
3. How does the final guidance address 21 CFR Part 11 compliance?
The FDA clarifies that validation focus should be risk-based and tied to record integrity. Manufacturers should concentrate assurance activities on functions that affect electronic records, audit trails, signatures, and data integrity. Native digital records (logs, audit trails) are acceptable evidence, reducing reliance on screenshots or paper.
4. Does the final CSA guidance encourage using system logs and audit trails as validation evidence (instead of screenshots)?
Yes. The final FDA CSA guidance supports leveraging native digital records, such as system logs, audit trails, and other data generated and maintained by the software, as objective assurance evidence. This reduces the need for manual, paper-based documentation or duplicating evidence (e.g., screenshots) that the system already retains electronically.
When using digital records as evidence, manufacturers should ensure that the records are appropriate for the intended use and that their accuracy and authenticity are considered as part of the risk-based assurance approach.
5. What does the FDA expect for software vendor assessments?
The final CSA guidance adds a dedicated vendor evaluation subsection. It recommends assessing vendor cybersecurity posture, development practices, certifications, and documentation, while recognizing manufacturers often have limited access. Remote assessments, SOC reports, SBOMs (software bill of materials), and accreditation reviews are encouraged.
Draft vs Final CSA Guidance Comparison Table
| Topic | 2022 Draft Guidance | 2026 Final Guidance |
|---|---|---|
| Scope & Purpose | Introduced shift from CSV to risk-based CSA. | Reorganizes and expands content; reinforces same risk-based model. |
|
Definitions Section |
No formal section: cloud terms referenced loosely. |
New section with explicit definitions for SaaS, PaaS, IaaS, cloud deployment models. |
| AI/ML Clarity | AI/ML referenced generically. | AI/ML explicitly included as technologies requiring risk-based assurance. |
| Cybersecurity Requirements | Cybersecurity lightly referenced; no clear expectations. | Strong emphasis on cybersecurity evidence: SOC reports, SBOMs, vendor security documentation. |
| 21 CFR Part 11 Guidance | Limited clarity on how Part 11 interacts with CSA. | Risk-based application, focusing on record integrity; encourages native digital records over screenshots. |
| Vendor Evaluation | Mentioned but not deeply detailed. | New subsection: vendor audits, certifications, dev practices, cybersecurity posture, remote assessments. |
| Digital Records / Evidence | Encouraged but not emphasized. | Strong recommendation to use digital logs, audit trails, automated testing evidence. |
| Examples & Appendix | 3 examples. | Expanded appendix + new Example 4 for SaaS PLM with auto-updates. |
| Regulatory Change Handling | General references to documentation expectations. | Guidance on when changes require 30-day notices vs annual reports. |
| Cloud/SaaS Updates | Not well detailed. | Explicit guidance on handling cloud releases, vendor updates, and continuous delivery. |
Automatic Updates in SaaS (FDA CSA)
The FDA’s final Computer Software Assurance (CSA) guidance recognizes that many production and quality systems are delivered as SaaS and receive automatic updates. In the SaaS example, FDA describes a practical expectation: the SaaS vendor should provide documentation that summarizes the update, the testing performed, and the test results for the functions relevant to the manufacturer’s intended use.
The manufacturer should then assess the change’s potential impact, perform risk-based assurance testing as appropriate, and maintain a record of the risk assessment and assurance activities performed.
This approach supports a modern, risk-based model that is consistent with the CSA objective: establishing and maintaining confidence that software is fit for its intended use, without unnecessary burden.
How FIVE Validation supports these CSA “Automatic Updates” good practices
In GO!FIVE®, customers can maintain a structured and inspection-ready trail of update oversight by:
- Capturing vendor release evidence (release notes, change summaries, testing summaries) as part of the lifecycle records
- Performing a documented impact assessment per release, focusing on the intended use and GxP-relevant functions
- Executing risk-based assurance testing targeted to what changed (rather than re-testing everything)
- Keeping the full record in a single, controlled space (including risk rationale and test evidence), which supports efficient oversight and audit readiness
In other words, FIVE Validation enables the “vendor evidence + manufacturer impact assessment + risk-based testing + retained record” model that FDA highlights for SaaS automatic updates.
